			Age (	(years)		HbF (%)			
	Ν	Sex (M/F)	Median [IQR]	Min	Max	Median [IQR]	Min	Max	
ABUJA	145	64/81	16[12-22]	5	41	9.4 [5.80 - 13.90]	0.8	28.0	
LAGOS	638	314/324	14 [9 -23]	5	60	$5.8 [3.40 - 9.30]^{a}$	0.8	32.0	
ZARIA	223	97/126	18 [10-23]	5	45	6.1 [4.00 – 10.50] <sup>b</sup>	0.8	23.3	
TOTAL	1006	475/531	15 [9 -23]	5	60	6.69 [3.67 – 11.02]	0.8	32.0	

Supplementary Table 1. Characteristics of the Nigerian cohort included in the GWAS

a: Significantly lower HbF levels compared to patients in ABUJA site ( $P = 1.77 \times 10^{-9}$ ). b: Significantly lower HbF levels compared to patients in ABUJA site ( $P = 5.1 \times 10^{-5}$ ).



Supplementary Figure 1. (a) The pricincipal component analysis shows individuals from the Southern Nigeria (below the dashed line) and those from the Northen Nigeria (above the dashed line). YRI: Yoruba in Ibadan population; LWK: Luhya in Webuye, Kenya; ASW: Americans of African Ancestry in Southwest USA. (b). The principal component analysis of the Nigerian cohort alongside the major population ancestries. AFR: Africa; AMR: America; EAS: East Asia; EUR: Europe.

Supplementally radie 2. Quanty control summar	Su	oplementary	Table 2.	Ouality	control	summar
---	----	-------------	----------	---------	---------	--------

QC step	Individuals excluded	SNPs excluded
Per-individual QC		
Genotype call rate < 90%*	77	
Sex discrepancy samples	21	
Heterozygosity outliers	20	
Genetically identical samples	20	
**SBeta+	6	
**Patients < 5 years	8	
Remaining individuals: 1006		
Per-marker QC		
SNP call rate < 97%		61,878
MAF < 1%		266,727
HWE $p < 10^{-8}$		5616 SNPs
Non-autosomal SNPs Remaining SNPs: <b>1,925,391</b>		44,294

\*Samples with genotype call rates < 90% were excluded from the Illumina Genome Studio software following our previously published GWAS quality control protocol. Samples excluded due to heterozygosity outliers were mainly from the region where consanguinity is common. #: Of these, 50941 SNPs were zeroed during pre-QC steps in the Genome studio.

Chr/Gene	Top SNP	MAF	p-value	$LD(D', r^2)$	Sample	Population	Cohort	Study type	Authors
					size				
Chr 2:									
BCL11A									
	rs1427407	0.14	2.5 x 10 <sup>-20</sup>	0.94, 0.16	179	Northern Europeans	Twins UK	GWAS	[1]
	rs4671393	0.27	2.0 x 10 <sup>-42</sup>	1.0, 0.23	1275	African-American	CSSCD	GWAS	[2]
	rs766432	0.28	2.61 x 10 <sup>-21</sup>	1.0, 0.23	848	African-American	CSSCD	GWAS	[3]
	rs766432	0.276	5.36 x 10 <sup>-58</sup>	1.0, 0.23	2040	African-American	Multicentre- study	Meta- analysis	[4]
	rs7606173	0.45	5.14 x 10 <sup>-16</sup>	1.0, 0.91	440	African_American	SIT Trial	GWAS	[5]
	rs1427407	0.22	3.74 x 10 <sup>-53</sup>	0.94, 0.16	1213	East-Africa	Tanzania	GWAS	[6]
	rs1896295	0.25	2.49 x 10 <sup>-26</sup>	1.0, 0.22	585	African-American	BCM & SCCRIP	GWAS	[7]
	rs6706648	0.41	4.96 x 10 <sup>-34</sup>		1006	West-Africa	Nigeria	GWAS	Current study

Supplementary Table 3. Previous HbF-associated genome-wide significant SNPs in three major loci

Chr 6: HBS1L-									
MYB									
	rs9399137	0.23	2.8 x 10 <sup>-27</sup>	1.0, 0.001	179	Northern Europeans	Twins UK study	GWAS	[1]
	rs9399137	0.06	5.0 x 10 <sup>-11</sup>	1.0, 0.001	1275	African- American	CSSCD	GWAS	[2]
	rs9494145	0.07	4.32 x 10 <sup>-</sup>	1.0, 0.59	2040	African- American	Multicentre	Meta- analysis	[4]
	rs9494145	0.05	2.42 x 10 <sup>-</sup>	1.0, 0.59	1213	East-Africa	Tanzania	GWAS	[6]
	rs116460276	0.02	3.06 x 10 <sup>-</sup>	1.0, 1.0	585	African- American	SIT trial	GWAS	[7]
	rs61028892	0.02	1.18 x 10 <sup>-9</sup>		1006	West-African	Nigeria	GWAS	Current study
Chr 11									
XmnI-HBG2	rs7482144	0.33	2.0 x 10 <sup>-30</sup>	-	179	Northern Europeans	Twins UK study	GWAS	[1]
XmnI-HBG2	rs7482144	0.07	4.0 x 10 <sup>-7</sup>	-	1275	African- American	CSSCD	GWAS	[2]
OR51B5/OR51B6	rs5006884	0.13	4.73 x 10 <sup>-8</sup>	-	848	African- American	CSSCD	GWAS	[3]

LD (D', r<sup>2</sup>) relationship between our lead SNP and SNPs reported in previous studies using LDlink: YRI (Yoruba in Ibadan, Nigeria) population in 1000 Genome Project[8]. CSSCD: Cooperative Study of SCD; BCM: Baylor College of Medicine cohort; SCCRIP: St. Jude Children' Research Hospital Sickle Cell Clinical Research and Intervention Program; SIT: Silent Infarct Transfusion.

					Scaled Summary Statistics		COJO output				
Annotation	SNP	Chr	Position	- Frequency	b	se	p-value	bJ	bJ_se	pJ	Overlap with annotation
GATA1	rs6706648*	2	60722040	0.413	-0.395	0.033	1.24 E-33	-0.288	0.039	1.32E-13	FALSE
GATA1	rs1427407	2	60718043	0.253	0.409	0.037	4.57E-28	0.257	0.044	5.88E-09	TRUE
HUDEP-2	rs6706648*	2	60722040	0.413	-0.395	0.033	1.24E-33	-0.292	0.039	4.98E-14	FALSE
HUDEP-2	rs1427407	2	60718043	0.253	0.409	0.038	2.86E-27	0.254	0.045	1.21E-08	FALSE
K562	rs6706648*	2	60722040	0.413	-0.395	0.033	1.24E-33	-0.292	0.039	4.89E-14	FALSE
K562	rs1427407	2	60718043	0.253	0.409	0.038	2.86E-27	0.254	0.045	1.20E-08	FALSE

#### Supplementary Table 4: fGCTA results for the BCL11A locus

GCTA-COJO p-value threshold:  $1 \times 10^{-5}$ , fGCTA enrichment parameter: x2.5; \* Peak SNP for this locus. Position: Chromosomal positions are in hg37; GATA1: GATA1 ChIP-seq on human peripheral derived blood-erythroblast; b = effect size, SE= standard error, p-value from the scaled summary statistics; bJ = effect size, sbJ\_se= standard error and pJ = p-value from a joint analysis of all the selected SNPs.

Chr	rsID	bp	EA	freq	β	se	р	βC	βC_se	pС
2	rs7565301	60496131	А	0.30169	0.104313	0.034342	0.002386	0.22691	0.034482	4.69E-11
2	rs6706648	60494905	Т	0.412525	-0.3947	0.032454	4.96E-34	-0.23121	0.035183	4.97E-11
2	rs7606173	60498316	С	0.434292	-0.39256	0.032912	8.50E-33	-0.2344	0.035687	5.09E-11
2	rs6729815	60496537	С	0.307157	0.105949	0.034167	0.001929	0.224669	0.034313	5.84E-11
2	rs7599488	60491212	Т	0.303181	0.101711	0.034315	0.003036	0.224745	0.034448	6.83E-11
2	rs6545817	60488044	Т	0.307271	0.095021	0.034126	0.005362	0.219086	0.03424	1.57E-10
2	rs6738440	60495106	G	0.27998	-0.36236	0.035081	5.20E-25	-0.23657	0.037066	1.75E-10
2	rs6709302	60500494	А	0.313347	-0.356	0.034868	1.79E-24	-0.23542	0.036905	1.78E-10
2	rs10189857	60486100	G	0.307654	0.093908	0.034117	0.005913	0.217889	0.034228	1.94E-10
2	rs13019832	60483436	А	0.428926	-0.28073	0.031961	1.58E-18	-0.20951	0.033245	2.93E-10
2	rs45606437	60495973	А	0.341182	-0.36801	0.033736	1.05E-27	-0.22505	0.035963	3.90E-10
2	rs6545816	60487726	С	0.340457	0.079935	0.033026	0.015506	0.207082	0.033104	3.96E-10

Supplementary Table 5. List of SNPs obtained after conditional analysis on *rs1427407*.

Here we showed only p-values  $\leq 10^{-10}$ . EA: effect allele;  $\beta =$  effect size; se: standard error; p= pvalue;  $\beta C =$  effect size after conditioning on rs1427407;  $\beta C$ \_se: standard error after conditioning on rs1427407.

<u>~</u>								
Chr	SNP	bp	A1	A2	Freq	b	se	р
2	rs10189857	60486100	G	А	0.426581	0.043076	0.015578	0.00569
2	rs6545816	60487726	А	С	0.456719	0.044903	0.015558	0.003899
2	rs6545817	60488044	С	Т	0.458004	0.045101	0.015567	0.003766
2	rs1427407	60490908	Т	G	0.152569	0.501033	0.021644	1.49E-118
2	rs7599488	60491212	Т	С	0.425	0.044047	0.01555	0.004616
2	rs1896294	60491939	С	Т	0.298913	0.331639	0.016968	4.59E-85
2	rs766432	60492835	С	А	0.145455	0.505857	0.022067	2.72E-116
2	rs11886868	60493111	С	Т	0.299012	0.330788	0.016955	9.07E-85
2	rs4671393	60493816	А	G	0.144763	0.505039	0.022111	1.80E-115
2	rs6706648	60494905	Т	$\mathbf{C}$	0.319071	-0.24288	0.016754	1.27E-47
2	rs6738440	60495106	G	А	0.288636	-0.20583	0.017407	2.90E-32
2	rs7565301	60496131	А	G	0.266897	0.020675	0.017494	0.237272
2	rs6729815	60496537	Т	С	0.463933	0.041718	0.015478	0.007031
2	rs1896295	60496951	Т	С	0.144664	0.504048	0.022052	1.25E-115
2	rs1896296	60496952	G	Т	0.144565	0.503899	0.022043	1.17E-115
2	rs7606173	60498316	С	G	0.435474	-0.29618	0.015701	2.29E-79

Supplementary Table 6. List of selected *BCL11A* SNPs from the 5060 UK Twins

A1: effect allele; A2: other allele; b = effect size; se: standard error; p = p-value; SNPs in grey refer to rs6706648 and rs7606173 that were investigated for fine-mapping in the white-British Twins' cohort.

Haplotype	Frequency	HbF effect	P-value
TGG	25.3	0.561	< 0.001
GGG	3.5	0.122	0.844
GAG	29.3	0.213	< 0.001
GGC	40.7	reference	

**Supplementary Table 7.** Haplotype association analysis of *BCL11A* SNPs (rs1427407-rs7565301-rs7606173) in the UK SCD patients

Dupplemen	ung nuble of	10011	results for the	inili locus							
Scaled Summary											
						Statist	ics	(	COJO or	utput	
Annotation	SNP	Chr	Position_b37	Frequency	b	se	p-value	bJ	bJ_se	pJ	<b>Overlap with annotation</b>
GATA1	rs61028892*	6	135418664	0.018	0.732	0.118	4.73E-10	0.753	0.119	2.18E-10	TRUE
GATA1	rs66650371	6	135418632	0.032	0.514	0.087	4.12E-09	0.531	0.088	1.74E-09	TRUE
HUDEP-2	rs61028892*	6	135418664	0.018	0.732	0.118	4.73E-10	0.753	0.119	2.14E-10	TRUE
HUDEP-2	rs66650371	6	135418632	0.032	0.514	0.087	4.12E-09	0.531	0.088	1.72E-09	TRUE
K562	rs61028892*	6	135418664	0.018	0.732	0.118	4.73E-10	0.756	0.119	2.14E-10	TRUE
K562	rs9399137	6	135419018	0.037	0.504	0.082	6.83E-10	0.521	0.083	3.01E-10	TRUE

### **Supplementary Table 8:** fGCTA results for the *HMIP* locus

GCTA-COJO p-value threshold:  $1 \times 10^{-5}$ , fGCTA enrichment parameter: x2.5; \* Peak SNP for this locus. Position: Chromosomal positions are in hg37; GATA1: GATA1 ChIP-seq on human peripheral derived blood-erythroblast; b = effect size, SE= standard error, p-value from the scaled summary statistics; bJ = effect size, sbJ\_se= standard error and pJ = p-value from a joint analysis of all the selected SNPs. **Supplementary Table 9.** Haplotype association analysis of *HBS1L-MYB* (rs61028892-rs9399137) in the UK SCD patients

Haplotype	Frequency	HbF effect	P-value
GC	5.0	0.486	< 0.001
CT	1.6	0.892	< 0.001
GT	93.5	reference	

Supplementary	v Table 10.	List of all	suggestive and	genome-wide	significant SNPs
~~rr	/			8	

chr	name	bp	A1	A2	freq	b	se	р
2	rs6706648	60494905	Т	С	0.412525	-0.3947	0.032454	4.96E-34
2	rs7606173	60498316	С	G	0.434292	-0.39256	0.032912	8.50E-33
2	rs45606437	60495973	А	AC	0.341182	-0.36801	0.033736	1.05E-27
2	rs1427407	60490908	Т	G	0.252982	0.409466	0.037563	1.14E-27
2	rs1896296	60496952	G	Т	0.2715	0.38149	0.0366	1.95E-25
2	rs11434093	60495961	С	CA	0.2695	0.383339	0.036793	2.04E-25
2	rs1896295	60496951	Т	С	0.271	0.381471	0.036691	2.56E-25
2	rs766432	60492835	С	А	0.271869	0.37791	0.036424	3.21E-25
2	rs1896294	60491939	С	Т	0.271372	0.378659	0.036553	3.80E-25
2	rs4671393	60493816	А	G	0.2735	0.377705	0.036513	4.44E-25
2	rs6738440	60495106	G	А	0.27998	-0.36236	0.035081	5.20E-25
2	rs11886868	60493111	С	Т	0.269384	0.379162	0.036752	5.92E-25
2	rs10195871	60493454	А	G	0.273857	0.373505	0.036484	1.35E-24
2	rs34211119	60493183	GT	G	0.275	0.373377	0.036562	1.75E-24
2	rs10172646	60493622	G	А	0.275	0.373377	0.036562	1.75E-24
2	rs6709302	60500494	А	G	0.313347	-0.356	0.034868	1.79E-24
2	rs7557939	60494212	G	А	0.274775	0.373549	0.036592	1.82E-24
2	rs7584113	60494176	А	G	0.2745	0.37325	0.036571	1.86E-24
2	rs13019832	60483436	А	G	0.428926	-0.28073	0.031961	1.58E-18
2	rs45484694	60483892	CT	С	0.230143	0.328752	0.039205	5.05E-17
2	rs11692396	60483603	G	А	0.223161	0.327615	0.039257	7.10E-17
2	rs72962585	60502567	G	А	0.220825	-0.29849	0.038328	6.82E-15
2	rs58789059	60509717	А	G	0.172465	-0.27711	0.0417	3.03E-11
2	rs7340264	60509394	А	G	0.185572	-0.26581	0.040105	3.40E-11
2	rs72962596	60515110	Т	С	0.0996	-0.33283	0.052535	2.37E-10
2	rs72962586	60504631	Т	С	0.101392	-0.3265	0.051566	2.42E-10
2	rs6732518	60481462	С	Т	0.298387	0.226463	0.036187	3.90E-10
2	rs72962592	60510666	Т	С	0.163519	-0.26563	0.042757	5.22E-10
2	rs72962602	60516470	G	А	0.164343	-0.26291	0.042616	6.86E-10
2	rs555276704	60528808	G	GTAA	0.16633	-0.26019	0.042609	1.02E-09
2	rs72964419	60528663	Т	С	0.160263	-0.26403	0.043291	1.07E-09
2	rs79059225	60528627	Т	С	0.164813	-0.25899	0.042683	1.30E-09
2	rs66488669	60507448	G	А	0.230343	-0.21291	0.037931	1.99E-08
2	rs4672393	60470519	А	С	0.379602	-0.18147	0.032941	3.61E-08
2	rs114125602	60513084	А	G	0.027638	-0.5223	0.096339	5.91E-08
2	rs72964414	60523168	Т	С	0.148851	-0.21822	0.044088	7.44E-07
6	rs61028892	135097526	С	G	0.017982	0.732037	0.120351	1.18E-09
6	rs9399137	135097880	С	Т	0.037276	0.503912	0.083658	1.71E-09
6	rs35786788	135097904	А	G	0.037276	0.503912	0.083658	1.71E-09
6	rs66650371	135097494	Т	TTAC	0.032096	0.513867	0.089748	1.03E-08
6	rs148826327	135078218	А	G	0.016	0.723182	0.127556	1.43E-08
6	rs115099895	135104618	А	G	0.034328	0.464427	0.086831	8.86E-08
6	rs114603312	135104880	С	Т	0.034328	0.464427	0.086831	8.86E-08
6	rs114398597	135107536	G	А	0.034363	0.463423	0.086834	9.45E-08

9	rs115555854	84339933	А	С	0.014955	-0.72726	0.130523	2.52E-08
11	rs1406381	62301213	G	Т	0.320344	-0.16572	0.03341	7.04E-07
14	rs191465524	52721225	G	Т	0.015936	-0.63712	0.123409	2.44E-07
14	rs188152509	52740738	G	С	0.01592	-0.63708	0.123406	2.44E-07
15	rs140496989	89619296	А	G	0.045817	-0.42712	0.077342	3.34E-08
15	rs78432130	89643261	G	Т	0.045862	-0.40726	0.077303	1.38E-07
15	rs137993810	89628452	G	С	0.043327	-0.41851	0.079446	1.38E-07
15	rs78973372	89589437	Т	G	0.045364	-0.40542	0.077696	1.81E-07
15	rs146039045	89616003	А	G	0.055224	-0.3489	0.069713	5.59E-07
16	rs188481235	1446101	Т	С	0.019901	-0.54714	0.111648	9.56E-07
18	rs58817161	10818373	С	Т	0.017396	-0.63287	0.117935	8.04E-08
18	rs142386135	10819008	G	А	0.017396	-0.63287	0.117935	8.04E-08
18	rs143311786	10820712	G	А	0.017396	-0.63287	0.117935	8.04E-08



**Supplementary Figure 2:** UCSC plot for the *BCL11A* locus. Tracks in order: log10 p-values for variants; GATA1 ChIP-seq annotation; HUDEP-2 annotation; K562 annotation; genes in this locus.



**Supplementary Figure 3:** UCSC plot for the *HMIP* locus. Tracks in order: log10 p-values for variants; GATA1 ChiP-seq annotation; HUDEP-2 annotation; K562 annotation; genes in this locus.



Supplementary Figure 4. Regional Association plot of SLC28A3



Supplementary Figure 5. Regional Association plot of TICRR



Supplementary Figure 6. Regional Association plot of PIEZO2

					African-American cohort						
					Cross-sectional (BCM & SCCRIP)			Longitudinal (N = 326) <sup>1</sup>		Longitudinal (N = 326) <sup>2</sup>	
Chr	Nearest gene	SNP	Position	EA/OA	EAF	β	P-value	β	P-value	β	P-value
9	SLC28A3	rs115555854	84339933	A/C	0.006	-	-	-0.53	0.16	-0.38	0.25
11	SCGB1D4	rs1406381	62301213	G/T	0.4482	-0.05425	0.3413	0.043	0.57	0.025	0.72
14	PSMC6	rs191465524	52721225	G/T	0.0147	-0.1701	0.4665	-0.2	0.64	-0.21	0.58
14	PSMC6	rs188152509	52740738	G/C	0.0147	-0.1701	0.4665	-0.2	0.64	-0.21	0.58
15	TICRR	rs78973372	89589437	T/G	0.0242	0.03606	0.8364	0.27	0.19	0.23	0.22
15	TICRR	rs146039045	89616003	A/G	0.0302	-0.03462	0.8264	0.27	0.17	0.25	0.16
15	TICRR	rs140496989	89619296	A/G	0.0242	0.03606	0.8364	0.25	0.17	0.23	0.18
15	TICRR	rs137993810	89628452	G/C	0.0233	0.05119	0.7731	0.31	0.14	0.27	0.16
15	TICRR	rs78432130	89643261	G/T	0.0242	0.03606	0.8364	0.27	0.19	0.23	0.22
16	CLCN7	rs188481235	1446101	T/C	0.0173	0.1487	0.4854	0.54	0.061	0.38	0.15
18	PIEZO2	rs58817161	10818373	C/T	0.0164	-0.06301	0.7744	-2.4	0.00071	-2.5	0.00028
18	PIEZO2	rs142386135	10819008	G/A	0.0138	-0.1473	0.5341	-2.4	0.00071	-2.5	0.00028
18	PIEZO2	rs143311786	10820712	G/A	0.0164	-0.06301	0.7744	-0.24	0.00071	-2.5	0.00028

## Supplementary Table 11. Summary statistics of African-American data for replication

Chr: Chromosome; SNP: reference ID for the Single Nucleotide Polymorphism; EA: Effect allele; OA: Other allele; EAF: Effect allele frequency;  $\beta$ : allelic effect size; N = sample size; BCM: Baylor College of Medicine cohort; SCCRIP: St. Jude Children' Research Hospital Sickle Cell Clinical Research and Intervention Program.

1: Longitudinal analysis of HbF at ages 1-6: (6 measurements per person, for a total of 1956 data points). The analysis was adjusted for age, sex, Hydroxyurea therapy, principal components 1-5, and the SNP-age interaction; 2: Longitudinal analysis, adjusting for age, sex, Hydroxyurea therapy, principal components 1-5, the SNP-age interaction, and 11-SNP polygenic score for HbF (PGS<sup>HbF</sup>) as detailed in [7].

Chr	Locus	SNP	Position	EA/OA	EAF	Ν	p-value	Direction of effect
								allele
1	WDR78	rs77479749	66828256	C/T	0.089	3554	5.74 x 10 <sup>-7</sup>	+
2	BCL11A	rs1427407	60490908	T/G	0.237	3572	1.83 x 10 <sup>-109</sup>	+
2	TEX51	rs116591810	126849099	T/C	0.035	3546	5.54 x 10 <sup>-7</sup>	-
4	GRID2	rs539530558	93555532	T/G	0.01	1759	4.67 x 10 <sup>-7</sup>	-
5	AC01460.1	rs1560177	23322878	C/T	0.189	3562	6.5 x 10 <sup>-7</sup>	+
6	HBS1L-MYB	rs9399137	135097880	C/T	0.044	3562	1.77 x 10 <sup>-27</sup>	+
6	NKAIN2	rs138298800	124625064	A/G	0.011	1179	2.69 x 10 <sup>-7</sup>	-
6	ATP5MGP2	rs149569206	122875198	A/T	0.016	3504	1.16 x 10 <sup>-7</sup>	-
9	SLC28A3	rs115555854	84339933	A/C	0.015	1003	2.73 x 10 <sup>-8</sup>	-
11	OR52S1P	rs4531463	5078160	A/G	0.074	1375	2.03 x 10 <sup>-10</sup>	+
14	AC005520.4	rs115521884	73844597	C/A	0.079	355	9.25 x 10 <sup>-7</sup>	+
17	FAAP100	rs12675	81540246	A/G	0.272	2926	7.69 x 10 <sup>-7</sup>	+
21	AF254983.2	rs79114373	10399098	T/C	0.117	579	8.25 x 10 <sup>-7</sup>	-

# Supplementary Table 12. Genome-wide significant and suggestive loci obtained from the meta-analysis.

Chr: Chromosome; SNP: reference ID for the Single Nucleotide Polymorphism; EA: Effect allele; OA: Other allele; EAF: Effect allele frequency; N = sample size.

## References

- Menzel S, Garner C, Gut I, Matsuda F, Yamaguchi M, Heath S, Foglio M, Zelenika D, Boland A, Rooks H, et al: A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. *Nat Genet* 2007, 39:1197-1199.
- 2. Lettre G, Sankaran VG, Bezerra MA, Araujo AS, Uda M, Sanna S, Cao A, Schlessinger D, Costa FF, Hirschhorn JN, Orkin SH: **DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease.** *Proc Natl Acad Sci U S A* 2008, **105**:11869-11874.
- 3. Solovieff N, Milton JN, Hartley SW, Sherva R, Sebastiani P, Dworkis DA, Klings ES, Farrer LA, Garrett ME, Ashley-Koch A, et al: Fetal hemoglobin in sickle cell anemia: genomewide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. *Blood* 2010, 115:1815-1822.
- Bae HT, Baldwin CT, Sebastiani P, Telen MJ, Ashley-Koch A, Garrett M, Hooper WC, Bean CJ, Debaun MR, Arking DE, et al: Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood 2012, 120:1961-1962.
- Bhatnagar P, Purvis S, Barron-Casella E, DeBaun MR, Casella JF, Arking DE, Keefer JR: Genome-wide association study identifies genetic variants influencing F-cell levels in sickle-cell patients. *Journal of Human Genetics* 2011, 56:316-323.
- 6. Mtatiro SN, Singh T, Rooks H, Mgaya J, Mariki H, Soka D, Mmbando B, Msaki E, Kolder I, Thein SL, et al: Genome wide association study of fetal hemoglobin in sickle cell anemia in Tanzania. *PLoS One* 2014, **9:**e111464.
- Rampersaud E, Kang G, Palmer LE, Rashkin SR, Wang S, Bi W, Alberts NM, Anghelescu D, Barton M, Birch K, et al: A polygenic score for acute vaso-occlusive pain in pediatric sickle cell disease. *Blood Adv* 2021, 5:2839-2851.
- 8. Machiela MJ, Chanock SJ: **LDlink: a web-based application for exploring populationspecific haplotype structure and linking correlated alleles of possible functional variants.** *Bioinformatics* 2015, **31:**3555-3557.